Samuel F. Gerard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Samuel F. Gerard has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Matthew K. Higgins
University of Oxford
2 shared publications - Afroditi Maria Zaki
Structural Bioinformatics and Computational Biochemistry, Department of Biochemistry, University of Oxford, Oxford, UK
1 shared publication Alan N. Engelman
Department of Medicine, Harvard Medical School, Boston, USA
1 shared publication- Angela M. Minassian
The Jenner Institute, University of Oxford, UK
1 shared publication Ashwani Sharma
Laboratory of Biomolecular Research, Division of Biology and Chemistry, Paul Scherrer Institut, 5232 Villigen PSI, Switzerland
1 shared publication- Belinda Suzette Hall
Discipline of Microbes, Infection & Immunity, School of Biosciences, Faculty of Health and Medical Sciences, University of Surrey
1 shared publication
Latest Publications
- 3 August 2020
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 27 (9) , 855-862
Intrinsic curvature of the HIV-1 CA hexamer underlies capsid topology and interaction with cyclophilin A
The mature retrovirus capsid consists of a variably curved lattice of capsid protein (CA) hexamers and pentamers. High-resolution structures of the curved assembly, or in complex with host factors, have not been available. By devising cryo-EM methodologies for exceedingly flexible and pleomorphic assemblies, we have determined cryo-EM structures of apo-CA hexamers and in complex with cyclophilin A (CypA) at near-atomic resolutions. The CA hexamers are intrinsically curved, flexible and asymmetric, revealing the capsomere and not the previously touted dimer or trimer interfaces as the key contributor to capsid curvature. CypA recognizes specific geometries of the curved lattice, simultaneously interacting with three CA protomers from adjacent hexamers via two noncanonical interfaces, thus stabilizing the capsid. By determining multiple structures from various helical symmetries, we further revealed the essential plasticity of the CA molecule, which allows formation of continuously curved conical capsids and the mechanism of capsid pattern sensing by CypA.
- 3 August 2020
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 27 (9) , 855-862
Intrinsic curvature of the HIV-1 CA hexamer underlies capsid topology and interaction with cyclophilin A
The mature retrovirus capsid consists of a variably curved lattice of capsid protein (CA) hexamers and pentamers. High-resolution structures of the curved assembly, or in complex with host factors, have not been available. By devising cryo-EM methodologies for exceedingly flexible and pleomorphic assemblies, we have determined cryo-EM structures of apo-CA hexamers and in complex with cyclophilin A (CypA) at near-atomic resolutions. The CA hexamers are intrinsically curved, flexible and asymmetric, revealing the capsomere and not the previously touted dimer or trimer interfaces as the key contributor to capsid curvature. CypA recognizes specific geometries of the curved lattice, simultaneously interacting with three CA protomers from adjacent hexamers via two noncanonical interfaces, thus stabilizing the capsid. By determining multiple structures from various helical symmetries, we further revealed the essential plasticity of the CA molecule, which allows formation of continuously curved conical capsids and the mechanism of capsid pattern sensing by CypA.
- Open Access
- 1 August 2020
- Published by Elsevier in Molecular Cell
- Vol. 79 (3) , 406-415.e7
Structure of the Inhibited State of the Sec Translocon
- 1 August 2020
- Published by Elsevier in Molecular Cell
- Vol. 79 (3) , 406-415.e7
Open AccessStructure of the Inhibited State of the Sec Translocon
- Open Access
- 27 May 2019
- Published by Springer Nature in Nature Microbiology
- Vol. 4 (9) , 1497-1507
Structural basis for inhibition of Plasmodium vivax invasion by a broadly neutralizing vaccine-induced human antibody
The most widespread form of malaria is caused by Plasmodium vivax. To replicate, this parasite must invade immature red blood cells through a process requiring interaction of the P. vivax Duffy binding protein (PvDBP) with its human receptor, the Duffy antigen receptor for chemokines. Naturally acquired antibodies that inhibit this interaction associate with clinical immunity, suggesting PvDBP as a leading candidate for inclusion in a vaccine to prevent malaria due to P. vivax. Here, we isolated a panel of monoclonal antibodies from human volunteers immunized in a clinical vaccine trial of PvDBP. We screened their ability to prevent PvDBP from binding to the Duffy antigen receptor for chemokines, and their capacity to block red blood cell invasion by a transgenic Plasmodium knowlesi parasite genetically modified to express PvDBP and to prevent reticulocyte invasion by multiple clinical isolates of P. vivax. This identified a broadly neutralizing human monoclonal antibody that inhibited invasion of all tested strains of P. vivax. Finally, we determined the structure of a complex of this antibody bound to PvDBP, indicating the molecular basis for inhibition. These findings will guide future vaccine design strategies and open up possibilities for testing the prophylactic use of such an antibody.
- 27 May 2019
- Published by Springer Nature in Nature Microbiology
- Vol. 4 (9) , 1497-1507
Open AccessStructural basis for inhibition of Plasmodium vivax invasion by a broadly neutralizing vaccine-induced human antibody
The most widespread form of malaria is caused by Plasmodium vivax. To replicate, this parasite must invade immature red blood cells through a process requiring interaction of the P. vivax Duffy binding protein (PvDBP) with its human receptor, the Duffy antigen receptor for chemokines. Naturally acquired antibodies that inhibit this interaction associate with clinical immunity, suggesting PvDBP as a leading candidate for inclusion in a vaccine to prevent malaria due to P. vivax. Here, we isolated a panel of monoclonal antibodies from human volunteers immunized in a clinical vaccine trial of PvDBP. We screened their ability to prevent PvDBP from binding to the Duffy antigen receptor for chemokines, and their capacity to block red blood cell invasion by a transgenic Plasmodium knowlesi parasite genetically modified to express PvDBP and to prevent reticulocyte invasion by multiple clinical isolates of P. vivax. This identified a broadly neutralizing human monoclonal antibody that inhibited invasion of all tested strains of P. vivax. Finally, we determined the structure of a complex of this antibody bound to PvDBP, indicating the molecular basis for inhibition. These findings will guide future vaccine design strategies and open up possibilities for testing the prophylactic use of such an antibody.
- 1 July 2018
- Published by Elsevier in Journal of Structural Biology
- Vol. 203 (1) , 62-70
Cep120 promotes microtubule formation through a unique tubulin binding C2 domain
- 1 July 2018
- Published by Elsevier in Journal of Structural Biology
- Vol. 203 (1) , 62-70
Cep120 promotes microtubule formation through a unique tubulin binding C2 domain